AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31162376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drainage seton
Number of subjects: 60
Study 31162376 — intervention group
Group type: COMPARATOR
Intervention: External anal sphincter-sparing seton
Number of subjects: 60
Study 28920540 — intervention group
Group type: COMPARATOR
Intervention: Conventional module ligation
Number of subjects: 120
Study 28920540 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight module ligation
Number of subjects: 120
Study 26052069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate hip osteoarthritis walking on a treadmill with increasing speeds.
Number of subjects: 36
Study 23640485 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 20662976 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI + PV isolation (PVI) (Group B)
Number of subjects: 48
Study 20662976 — intervention group
Group type: COMPARATOR
Intervention: CTI ablation (Group A)
Number of subjects: 48
Study 19639058 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with freeze-dried bone allograft (FDBA; group A)
Number of subjects: 12
Study 19639058 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft (ABBG; group B)
Number of subjects: 12
Study 19639058 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft/mineralized collagen bone substitute (ABBG/MCBS; group C)
Number of subjects: 12
Study 17371357 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg)
Number of subjects: 60
Study 17371357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (50 mg)
Number of subjects: 60
Study 17371357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15234287 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N Trial (new subfoveal CNV)
Number of subjects: 789
Study 15234287 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B Trial (predominantly hemorrhagic CNV)
Number of subjects: 789
Study 11576883 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg of paricalcitol intravenously with the hemodialysis session three times weekly for 12 weeks
Number of subjects: 31
Study 11576883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11576883 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 31
Study 9305517 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized start design
Number of subjects: 0
Study 9305517 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized withdrawal design
Number of subjects: 0
Study 9305517 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers using neuroimaging or other measures
Number of subjects: 0
Study 7870844 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 10
Study 7870844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7870844 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPP (0.5 mg/kg)
Number of subjects: 10
Study 7870844 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam + MCPP
Number of subjects: 10
Study 2680231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of [1-13C]leucine (0.05 g/kg)
Number of subjects: 10
Study 2680231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of unlabelled leucine (4 g)
Number of subjects: 10
Study 767080 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 0
Study 767080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric responders
Number of subjects: 0
Study 31654593 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-AKI patients
Number of subjects: 572
Study 31654593 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of AKI stage
Number of subjects: 572
Study 31654593 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-AKI patients discharged from hospital
Number of subjects: 572
Study 31654593 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-AKI patients at 90-days post-discharge
Number of subjects: 572
Study 31654593 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-AKI patients at 12 months post-discharge
Number of subjects: 572
Study 30317381 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 349
Study 30317381 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 349
Study 27637753 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox FreeHands FlexiVoice
Number of subjects: 40
Study 26100988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia‐Modified Albumin (IMA) levels in the AP group
Number of subjects: 16
Study 26100988 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase levels in the AP group
Number of subjects: 16
Study 26100988 — intervention group
Group type: COMPARATOR
Intervention: Control group (Sham)
Number of subjects: 16
Study 24156204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 8% arginine, calcium carbonate, and 1,000 ppm MFP (Colgate Sensitive Pro‐Relief)
Number of subjects: 100
Study 24156204 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fluoride dentifrice (Colgate Cibaca)
Number of subjects: 100
Study 21474474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg before operation and 75 mg twice daily for 5 days)
Number of subjects: 70
Study 21474474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19347770 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS and fibre-enriched tube feeding
Number of subjects: 19
Study 19347770 — intervention group
Group type: COMPARATOR
Intervention: No residue tube feeding (non-FOS group)
Number of subjects: 19
Study 22648123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid transvaginal NOTES (TV group)
Number of subjects: 60
Study 22648123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid transumbilical NOTES (TU group)
Number of subjects: 60
Study 22648123 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL group)
Number of subjects: 60
Study 16272755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specific drugs not mentioned)
Number of subjects: 0
Study 12625832 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 energy% (E%) fat meal
Number of subjects: 26
Study 12625832 — intervention group
Group type: COMPARATOR
Intervention: 20 energy% (E%) fat meal
Number of subjects: 26
Study 12625832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 energy% (E%) fat meal
Number of subjects: 26
Study 12625832 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) administration
Number of subjects: 26
Study 10550466 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day alendronate
Number of subjects: 262
Study 10550466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day alendronate
Number of subjects: 262
Study 10550466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 8526832 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude acclimatization (HA) for 16 days followed by reexposure (RA) for 30 hours at 4300 m
Number of subjects: 6
Study 8526832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reexposure to high altitude (RA) after acclimatization
Number of subjects: 6
Study 2081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg
Number of subjects: 0
Study 2081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 40 mg
Number of subjects: 0
Study 2081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 0
Study 2081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg and 40 mg
Number of subjects: 0
Study 2081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg, 20 mg, and 40 mg
Number of subjects: 0
Study 120549 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol (900 mg/day for 21 days)
Number of subjects: 0
Study 11159568 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus (dry extract tablets) one tablet daily for three consecutive cycles
Number of subjects: 170
Study 11159568 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus (dry extract tablets)
Number of subjects: 170
Study 11159568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 30651139 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture plus electroacupuncture (EA)
Number of subjects: 68
Study 30651139 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus placebo EA without electrical stimulation
Number of subjects: 68
Study 29554012 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 36
Study 29554012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 36
Study 29554012 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise Control (Con)
Number of subjects: 36
Study 27513088 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOMS Full
Number of subjects: 94
Study 27513088 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Rating Scale (ORS)-only
Number of subjects: 94
Study 27513088 — intervention group
Group type: EXPERIMENTAL
Intervention: Session Rating Scale (SRS)-only
Number of subjects: 94
Study 24724771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice starch prethickened lactose-free milk protein-based infant formula
Number of subjects: 132
Study 24724771 — intervention group
Group type: COMPARATOR
Intervention: Standard lactose-containing milk-based infant formula (control)
Number of subjects: 132
Study 22613545 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 0
Study 22613545 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 0
Study 22613545 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg/d and 300 mg/d
Number of subjects: 0
Study 20434961 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/d of DHA orally for 24 weeks
Number of subjects: 485
Study 20434961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 17274711 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + ACBP
Number of subjects: 27
Study 17274711 — intervention group
Group type: COMPARATOR
Intervention: EMD
Number of subjects: 27
Study 16375040 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised letter
Number of subjects: 1322
Study 16375040 — intervention group
Group type: COMPARATOR
Intervention: Personalised letter plus brochure
Number of subjects: 1322
Study 12064984 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 107
Study 12064984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 10208225 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg daily)
Number of subjects: 12
Study 7842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg
Number of subjects: 8
Study 7842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 8
Study 7842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid 25 mg
Number of subjects: 8
Study 7842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid 50 mg
Number of subjects: 8
Study 7842188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 8
Study 2220345 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 2 weeks
Number of subjects: 62
Study 2220345 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets 1 tablet twice daily for 2 weeks
Number of subjects: 62
Study 2220345 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study 30019617 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group (n = 18)
Number of subjects: 37
Study 30019617 — intervention group
Group type: COMPARATOR
Intervention: Kicking-control group (n = 16)
Number of subjects: 37
Study 30019617 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group at 24 h post-heading
Number of subjects: 37
Study 30019617 — intervention group
Group type: COMPARATOR
Intervention: Heading group vs Kicking-control group at 24 h post-heading
Number of subjects: 37
Study 28432894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) treatment for OCD, PD/A, SAD, and GAD
Number of subjects: 0
Study 25921948 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine
Number of subjects: 20
Study 25921948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22996743 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact + resistance training (POWIR)
Number of subjects: 71
Study 22996743 — intervention group
Group type: COMPARATOR
Intervention: Exercise placebo (FLEX)
Number of subjects: 71
Study 22192583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (50 g daily)
Number of subjects: 0
Study 22192583 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study 20180667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant opioid dependent patients (N = 108)
Number of subjects: 108
Study 20180667 — intervention group
Group type: COMPARATOR
Intervention: General pregnant patients (N = 1,516)
Number of subjects: 108
Study 17022356 — intervention group
Group type: EXPERIMENTAL
Intervention: RPRS intervention
Number of subjects: 34
Study 17022356 — intervention group
Group type: COMPARATOR
Intervention: Informational control (IC)
Number of subjects: 34
Study 14674905 — intervention group
Group type: EXPERIMENTAL
Intervention: Five times weekly application of short-contact dithranol (SCD)
Number of subjects: 25
Study 14674905 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly application of short-contact dithranol (SCD)
Number of subjects: 25
Study 10505482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (150‐300 mg)
Number of subjects: 171
Study 10505482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 9069860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (treatment group, n = 30) with bilateral elastic bands exerting pressure on the wrist during the perioperative period.
Number of subjects: 90
Study 9069860 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (placebo group, n = 30) with elastic bands incapable of acupressure placed on wrists.
Number of subjects: 90
Study 9069860 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30) receiving routine nursing and medical interventions for nausea and vomiting.
Number of subjects: 90
Study 1890788 — intervention group
Group type: EXPERIMENTAL
Intervention: HL condition (high and low self-esteem children viewing both high and low SR criterion models)
Number of subjects: 48
Study 1890788 — intervention group
Group type: COMPARATOR
Intervention: M condition (high and low self-esteem children viewing only a middle SR criterion model)
Number of subjects: 48
Study 1890788 — intervention group
Group type: EXPERIMENTAL
Intervention: HL condition (low self-esteem group)
Number of subjects: 48
Study 6187310 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gestagen therapy
Number of subjects: 69
Study 6187310 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cyclophosphamide, 5-fluorouracil, methotrexate, vinblastine)
Number of subjects: 69
Study 31971811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (six sessions including baseline assessment, diaphragmatic breath training, and biofeedback screens)
Number of subjects: 104
Study 31971811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 104
Study 30672381 — intervention group
Group type: EXPERIMENTAL
Intervention: MARTAS intervention (up to 6 individual-level sessions with a linkage coordinator over 90 days)
Number of subjects: 22
Study 28131423 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative use of angiotensin receptor blockers (ARBs)
Number of subjects: 1351
Study 28131423 — intervention group
Group type: COMPARATOR
Intervention: No renin-angiotensin-system inhibitors
Number of subjects: 1351
Study 28131423 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (ACEis)
Number of subjects: 1351
Study 27318344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Inflation (SI)
Number of subjects: 32
Study 27318344 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively Increased Positive End Expiratory Pressure (IP)
Number of subjects: 32
Study 27318344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 32
Study 23617767 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training program (3 hours a week for 10 weeks) in addition to standard care
Number of subjects: 0
Study 23617767 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 20733014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention group (expressive writing + psycho-education)
Number of subjects: 359
Study 20733014 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treatment)
Number of subjects: 359
Study 19542793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 19542793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 252
Study 16517548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 42283
Study 16517548 — intervention group
Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 42283
Study 12527544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for generalized anxiety disorder in primary care (CBT‐GAD/PC)
Number of subjects: 12
Study 12527544 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 12
Study 10664917 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (600 mg bid)
Number of subjects: 24
Study 10664917 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg bid)
Number of subjects: 24
Study 9769898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast release tablet (FR 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12
Study 9769898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-slow release tablet (FSR 150 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12
Study 9769898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular solution (i.m. 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12
Study 9769898 — intervention group
Group type: COMPARATOR
Intervention: Fast release tablet (FR 100 mg) vs Fast-slow release tablet (FSR 150 mg)
Number of subjects: 12
Study 7801652 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exploration (blindfolded, exploring real objects with hands)
Number of subjects: 0
Study 7801652 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor encoding (adequate hand movements without sensory contact)
Number of subjects: 0
Study 7801652 — intervention group
Group type: COMPARATOR
Intervention: Passive touch (no hand movements, based on sensory impressions)
Number of subjects: 0
Study 7801652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory encoding (passive touch at both encoding and test)
Number of subjects: 0
Study 3294190 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30-90 mg daily)
Number of subjects: 17
Study 3294190 — intervention group
Group type: COMPARATOR
Intervention: Indoramin (75-225 mg daily)
Number of subjects: 17
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D gamma passing rates (%GPs) with 3%/3 mm criterion
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D gamma passing rates (%GPs) with 3%/3 mm criterion
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV-specific 2D %GP gradient
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV-specific 3D %GP gradient
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D and 3D %GPs correlation
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body %GP with 3%/3 mm criterion
Number of subjects: 11
Study 29905004 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV-specific gamma evaluation
Number of subjects: 11
Study 28185274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 28185274 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 0
Study 28185274 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 0
Study 28185274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26409409 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the non-dominant motor cortex
Number of subjects: 34
Study 26409409 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the dominant motor cortex
Number of subjects: 34
Study 26409409 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 34
Study 26409409 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 34
Study 24496201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cut-off (HCO) membranes
Number of subjects: 12
Study 24496201 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-flux (PF) membranes
Number of subjects: 12
Study 21929768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity High Dose Exercise Augmentation (DEI)
Number of subjects: 330
Study 21929768 — intervention group
Group type: COMPARATOR
Intervention: Health Education Intervention Augmentation (HEI)
Number of subjects: 330
Study 18356552 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamins (folic acid 2 mg, vitamin B6 25 mg, and vitamin B12 0.5 mg)
Number of subjects: 173
Study 18356552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 17162709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2 (n = 16)
Number of subjects: 46